About a year ago, I began designing a graduate certificate program for American University focused on technology issues in arts management, and this past summer, I taught my first course focused on the intersection of technology and marketing. To open the course, I asked students to read Malcolm Gladwell's The Tipping Point, which if you haven't read it, describes how social epidemics evolve, providing a great platform to discuss word-of-mouth marketing and how technology can be used to ignite a movement.
Early in the book, Gladwell discusses "The Law of the Few," which boiled down is a riff on the 80/20 principle - 20% of the people are responsible for 80% of the work. As marketers, we latch onto this principle, as it correctly argues that if we can identify and cultivate relationships with a select group of influential people called "connectors," then our returns can be maximized. One connector can be worth his weight in gold, and easily as valuable as ten non-connectors.
As I was giving my lecture, it struck me that most non-profit arts organizations have designed their business models on the "Law of the Few" principle, not just in their approaches to marketing, but in how we program, fundraise and communicate. A previous supervisor of mine used to say that a grassroots movement begins with the grasstops. But if we are all focused on the few, are we ignoring the many?
I ask this question, because as society shifted away from a one way, web 1.0 world towards an interactive, web 2.0 one, the ways in which we do business and view the world radically changed. Previously companies had much more control of their brands as they could carefully craft messaging, but today, brands have a life of their own in the virtual universe. We used to seek out experts when we needed information, now we rely upon the collective of Wikipedia or Google (when was the last time you consulted an encyclopedia?). At one time knowledge was proprietary, but presently, a growing number of us look to the commons (and companies trying to maintain business models built upon charging for knowledge are struggling). We used to rely on authority figures to inform us, but now in moments of crisis, millions flock to Twitter, where we learned an hour before President Obama confirmed it that Osama Bin Laden had been killed.
I believe that many of us used to defer to the knowledge and experience of a small few, placing trust in their expertise to guide the rest of us. But when a handful of very powerful and experienced bankers plunged the world into a global economic crisis resulting in the loss of 40% of the world's wealth, the masses started to wonder if the few could be trusted to lead. In the web 1.0 world, most were passive recipients, willing to receive content as delivered. Today, the least among us now demands a seat at the table, and via web 2.0 technologies, an even playing field has begun to emerge.
So how will this affect the non-profit arts? Here are just a couple of examples:
The Citizen Critic (and the Future of Arts Journalism)
A couple of weeks ago, Barry Hessenius, former director of the California Arts Council, issued his annual list of the most influential people in the arts. On the list were a handful of notable bloggers, including Ian David Moss, Diane Ragsdale, Clay Lord, Doug McLennan and Thomas Cott, however not a single traditional journalist was mentioned as there wasn't a category for journalists. Was this an oversight, or a trend? Nielsen recently reported that 92% of consumers trusted word-of-mouth from friends and family, while only 58% trusted editorial content such as newspaper articles. Harvard University recently published a study that contended that average reader reviews on Amazon.com were just as trustworthy as book reviews from professional critics. Even Maura Judkis, a writer for the Washington Post, in her article for the NEA's blog ArtWorks states "readers of my generation, the Millennials, are more likely to want to see a movie or play because their friends like it than because a critic does." Word of mouth has always been powerful, but advances in technology have allowed connectors to broadcast their thoughts to followers instantaneously, and others, the opportunity to feed into social networking, user review sites like Yelp.com. So where does that leave us? Ask yourself - if you were visiting New York, and thousands of patrons had described a Broadway play positively in online reviews, would it have more of an impact on you than negative reviews by professional critics? [could this explain the mysterious success of Spiderman?]
Crowdfunding and Microfinancing
In her article "It is Broke, We Should Probably Fix It," Alexis Clements argues that many non-profit organizations chase a few, large foundations, whose money would have been public via taxation but is now controlled privately. She goes on to say that via grants from private foundations, wealthy individuals can "funnel money to organizations that will uphold their personal beliefs." That is a pretty charged statement, but I do wonder how often arts organizations manipulate their missions in order to receive a large grant or donation from a private funding source? How many arts organizations are alive today primarily due to the generosity of one or two major donors, and for those, do the donors in question wield too much influence? In 2008, President Obama demonstrated the power of the collective when he raised unprecedented amounts of money from small donations. As of August, the crowd funding website Kickstarter has raised $275 million in funding for projects, and has grown exponentially since its founding in 2009. And we aren't just talking about tiny amounts of funding either. The top 10 projects funded on Kickstarter all raised more than $1 million. And Microfinance website Kiva has leveraged $346 million in funds from 823,474 lenders to launch projects aimed at combating poverty in 63 different countries.
Crowdsourcing Curation and Programming
When I was at the Smithsonian, an internal debate was occurring about the "Art of Video Games" exhibit at the American Art Museum. The Smithsonian invited the public to help curate which video games would be featured in the exhibit, and in doing so, more than 3.7 million votes were cast by 119,000 people in 175 countries. Pretty impressive. However, questions began to arise about the role of the curator. For the most part, non-profit arts organizations are lead by artists with extensive training and sometimes decades of experience. As the resident experts in their fields, they are regularly called upon to make value judgements on what art to present, and how to present it. In the past, the public has remained a passive receiver of said art, but a growing number of patrons today would like to play a more active role. Technology has changed what used to be a one way conversation into a dialogue, and in turn, many community stakeholders now expect to be able to exercise their voice. I believe this phenomenon prompted Arts Journal editor Doug McLennan to host the "Lead or Follow" debate early this year. If you didn't catch it, here is a good recap.
Understandably, non-profit arts organizations have built models based on the "Law of the Few," and I am not advocating for the abandonment of those models. I am however suggesting that there is wisdom, money and resources to be found in the collective as well. This isn't an either/or proposition between the few and the many; it's a both/and situation. There is a significant role to play for the few and the many. But to tap into the collective, I believe we must become vital and essential to our communities again. I fear that for many non-profit arts organizations, if they were to disappear, we'd barely hear a whimper, when there should be protests in the streets.
Sunday, September 9, 2012
Monday, September 3, 2012
The War on Privacy!
With the explosion of social media activity, the rise of on line retailing, and real time bidding to reach the ever-increasing online audience, the spotlight is well and truly focussed on privacy. More than ever, this is a hot topic in the daily media and in the legislators’ agenda. This is a fertile field for shock headlines and fierce political debate, with prominent commercial players such
Wednesday, August 29, 2012
What’s happening in Innovative Marketing Strategy class?
We are nearing the completion of the unit on Innovative Marketing Strategies. The unit coordinator, Professor Donnel Briley (Chair of the Marketing Discipline), has imparted his truly global interpretation of marketing strategies. Having lived and studied in North America, Europe and Australia, Donnel’s vast cultural experiences are exemplified through the cases studies he presents.
My favorite
My favorite
Is Pharma Republican or Democrat? Follow the Money & Find Out
According to data reported by the Center for Responsive Politics, the pharmaceutical manufacturing sector has contributed nearly $12 million during the 2012 election cycle to federal candidates, parties, and outside groups (PACs). Fifty-eight percent (58%) of that went to Republicans. 61% of the funds came from PACs and 33% came from individuals. Around this time during the 2008 election cycle, the drug industry donated slightly more than $16 million, of which 51% went to Republicans.
NOTE: "The numbers on this page are based on contributions from PACs, soft money donors, and individuals giving $200 or more. (Only those groups giving $5,000 or more are listed here. Soft money applies only to cycles 1992-2002.) In many cases, the organizations themselves did not donate; rather the money came from the organization's PAC, its individual members or employees or owners, and those individuals' immediate families. Organization totals include subsidiaries and affiliates."
Here are the Top 20 pharma contributors in this cycle (click on image for an enlarged view):
To make it easier to see which pharma company employees/PACs are "Republican" and which are "Democrat," I prepared this chart from the table above (click on image for an enlarged view).
NOTE: "The numbers on this page are based on contributions from PACs, soft money donors, and individuals giving $200 or more. (Only those groups giving $5,000 or more are listed here. Soft money applies only to cycles 1992-2002.) In many cases, the organizations themselves did not donate; rather the money came from the organization's PAC, its individual members or employees or owners, and those individuals' immediate families. Organization totals include subsidiaries and affiliates."
Here are the Top 20 pharma contributors in this cycle (click on image for an enlarged view):
To make it easier to see which pharma company employees/PACs are "Republican" and which are "Democrat," I prepared this chart from the table above (click on image for an enlarged view).
Tuesday, August 28, 2012
Who Owns Your Social Media?
"Twitter just announced a complex, confusing, and developer-alienating system that restricts their once-open, always cherished but now apparently taken for granted API," complained Michael Spitz, SVP and Managing Director at Zemoga. "The new rules change the playing field for third party developers, establish caps on number of users, and shift guidelines to requirements across four categories of businesses that Danny Sullivan of Search Engine Land humorously characterized in Star Trek terms." Spitz characterized this as #TWITTERFAIL and he thinks the new rules "ruin the spirit of social media" and are "bad for healthcare" (see here).
Spitz's "rant" raises a couple of interesting issues that I will discuss with him this afternoon in a live Pharma Marketing Talk podcast (listen here or use the playback widget below).
First, the premise that changes to Twitter's API can be "bad" for healthcare is based upon the notion that Twitter has been or could be "good" for healthcare. I'm not sure what Spitz includes in his "healthcare" category. Since he works for an agency with pharmaceutical company clients, I am sure he includes the drug industry as part of what he means by healthcare. I'd like to focus at least part of today's discussion on how Twitter can be good (or bad) for the pharma industry's goals of selling more drugs.
I have written several articles about how pharma can use Twitter to help support patients (see "Supporting Patients via Twitter and Beyond" and "Use of Twitter for Patient Support") and criticized pharma for using Twitter (and blogs) to promote their products (ie, "market"; see "Novo Nordisk's Branded (Levemir) Tweet is Sleazy Twitter Spam!" and "AstraZeneca's Timely CRESTOR Branded Blog Post: Did It Violate Its Own Policy?"). My view is that Twitter has been good for pharma mainly in the public relations realm, which may or may not translate into increased drug sales.
Most tweets from pharmaceutical companies are about what they are doing in this therapeutic area or that therapeutic area (e.g., support for COPD, atrial fibrillation, diabetes innovation, etc.). Pharma tweets a lot about clinical study results (mostly the positive results) and news from medical conferences where they are exhibiting ("come to our booth"). They also tweet about investor presentations and other news about their company that Wall Street finds of interest.
None of those tweets do healthcare any good -- e.g., improve outcomes of drug treatment. They dn, however, provide benefit to pharma companies by getting them more attention by the media, which dutifully followup with articles based on these pharma "Tweet Releases."
Another issue related to the lament about the more and more restrictive Twitter API is the question "Who Owns your Social media?", which was brought to my attention by Phil Baumann of "Health is Social." Baumann is also a member of the Advisory Board at Mayo Clinic Center for Social Media, so he has a healthcare perspective beyond pharma.
I invited Baumann to be a guest on this afternoon's podcast, but he was not available. He did, however, send me some thoughts, one of which is:
"Too much emphasis has been placed on social media in general - at the expense of focusing on the only thing Healthcare or Pharma can own on the web: their own domains. Social Media should not be seen as the center of a web presence - ever. It's a tempting thought, but the reality is the other way around. Healthcare and Pharma organizations should learn [from] these API changes that they don't own anything on these social media sites. Many experts have laughed off blogging and traditional websites, but I still maintain that if you can't build your own solid presence on your own domain, you won't do well on social media in the long-run."
You should also read "The Over-promising of Healthcare Social Media" written by Baumann.
Here are a few other thoughts from Baumann on the Twitter API issue:
Spitz's "rant" raises a couple of interesting issues that I will discuss with him this afternoon in a live Pharma Marketing Talk podcast (listen here or use the playback widget below).
Listen to internet radio with Pharmaguy on Blog Talk Radio
First, the premise that changes to Twitter's API can be "bad" for healthcare is based upon the notion that Twitter has been or could be "good" for healthcare. I'm not sure what Spitz includes in his "healthcare" category. Since he works for an agency with pharmaceutical company clients, I am sure he includes the drug industry as part of what he means by healthcare. I'd like to focus at least part of today's discussion on how Twitter can be good (or bad) for the pharma industry's goals of selling more drugs.
I have written several articles about how pharma can use Twitter to help support patients (see "Supporting Patients via Twitter and Beyond" and "Use of Twitter for Patient Support") and criticized pharma for using Twitter (and blogs) to promote their products (ie, "market"; see "Novo Nordisk's Branded (Levemir) Tweet is Sleazy Twitter Spam!" and "AstraZeneca's Timely CRESTOR Branded Blog Post: Did It Violate Its Own Policy?"). My view is that Twitter has been good for pharma mainly in the public relations realm, which may or may not translate into increased drug sales.
Most tweets from pharmaceutical companies are about what they are doing in this therapeutic area or that therapeutic area (e.g., support for COPD, atrial fibrillation, diabetes innovation, etc.). Pharma tweets a lot about clinical study results (mostly the positive results) and news from medical conferences where they are exhibiting ("come to our booth"). They also tweet about investor presentations and other news about their company that Wall Street finds of interest.
None of those tweets do healthcare any good -- e.g., improve outcomes of drug treatment. They dn, however, provide benefit to pharma companies by getting them more attention by the media, which dutifully followup with articles based on these pharma "Tweet Releases."
Another issue related to the lament about the more and more restrictive Twitter API is the question "Who Owns your Social media?", which was brought to my attention by Phil Baumann of "Health is Social." Baumann is also a member of the Advisory Board at Mayo Clinic Center for Social Media, so he has a healthcare perspective beyond pharma.
I invited Baumann to be a guest on this afternoon's podcast, but he was not available. He did, however, send me some thoughts, one of which is:
"Too much emphasis has been placed on social media in general - at the expense of focusing on the only thing Healthcare or Pharma can own on the web: their own domains. Social Media should not be seen as the center of a web presence - ever. It's a tempting thought, but the reality is the other way around. Healthcare and Pharma organizations should learn [from] these API changes that they don't own anything on these social media sites. Many experts have laughed off blogging and traditional websites, but I still maintain that if you can't build your own solid presence on your own domain, you won't do well on social media in the long-run."
You should also read "The Over-promising of Healthcare Social Media" written by Baumann.
Here are a few other thoughts from Baumann on the Twitter API issue:
- The first thing that Healthcare and Pharma need to realize is that social software is pliant and tenuous. With social software, the tiniest tweaks can produce huge ramifications throughout a digital ecosystem.
- If the industries are going to be involved in social media, they need people on staff who can keep up with the technical changes that happen - in fact, they need to anticipate them and have plans to turn to when those changes take place.
- The average person probably only cares about Twitter clients - I suspect that Twitter will eventually whittle clients down to a very few. It already owns TweetDeck, but hasn't developed this asset much.
- The larger Healthcare/Pharma Enterprise impacts of the API changes are likely to be more in the area of data-mining, monitoring, metrics, etc. For example, Twitter might rate-limit calls for certain kinds of data - let's say a Pharma company or its vendor monitors for mentions of a drug and or keywords related to possible Adverse Events. Depending on the API changes over time, there may be limits to the amount of data that can be captured in a timely manner.
- None of what Twitter is doing with its API is at all unexpected - at least it shouldn't be. Ultimately, this is Twitter's product - albeit one that increasingly is becoming a virtual public utility.
Monday, August 27, 2012
McDonald's Sponsorship Case Study
Another Olympic Games has come and gone. And while Australian swimming may not have done as well as usual and are looking to review their performance, one organization that performed well in this period was McDonald's in Australia.
Obviously, we're not privy to the detailed financial results of McDonald's or their ROI on their significant investment as a major sponsor of the Olympics in London.
Obviously, we're not privy to the detailed financial results of McDonald's or their ROI on their significant investment as a major sponsor of the Olympics in London.
Thursday, August 23, 2012
The Blog Ate My Job!
I just received this comment via my "Contact Us" form:
The person who wrote chose to remain anonymous, so I will I will just refer to him/her as "Anon."
Anon claims that my writing "can and has cost people their jobs" and I assume he/she means his/her job because the subject line of the message was "lost my job."
First of all, it seems pretty unlikely that someone would be fired within hours after an "opnionated" and "unjust" blog post was made. Who can be so cruel to fire someone on the spot like that, especially someone who is just one of the "multiple hands" responsible for creating and approving ads?
I wonder if Anon also complained to Deborah Dick-Rath over at MM&M. She wrote her critical piece about the Replax print ad way before I did. She really ripped into the creative team: "And while the Relpax creative team put in a valiant effort, in the end, they were defeated by too many typefaces, too much copy, too many messages and a somewhat unfortunate choice in art direction."
I suppose she gets a free pass because she started out with praise, faint though it was.
Maybe this doesn't have anything to do with Relpax at all. I just can't recall, however, any recent critical posts I have made that may have gotten Anon fired.
Anyway, I assume Anon will be able to collect a couple of years of unemployment insurance, unless Congress refuses to extend that benefit. When I was laid off many years ago during the dotcom bust, I only received 26 weeks of unemployment insurance - damn George Bush and those Republicans!
"John, while the information you post online is informative and I am glad someone is bring (sic) things to public attention it is also can be estremely (sic) opnionated (sic) and unjust. Please realize that the actions you take in your writing can and has cost people their jobs. I work for an ad agency. I try my best to ensure my contributions are not to just sell drugs but to educate consumers. Pharma is about money but its also about making people better. When ads come out they are a result of multiple hands touching a piece from agency, to brand teams to mlr. When you decide to callout an ad you are impacting all those people. So please think about that when writing your blog. And look at what guidelines fda has set and where they still need to go. Rather then being a tatle (sic) tale be a solution maker."I'm guessing this has something to do with the post I made earlier today about "Retro Relpax" ads (here).
The person who wrote chose to remain anonymous, so I will I will just refer to him/her as "Anon."
Anon claims that my writing "can and has cost people their jobs" and I assume he/she means his/her job because the subject line of the message was "lost my job."
First of all, it seems pretty unlikely that someone would be fired within hours after an "opnionated" and "unjust" blog post was made. Who can be so cruel to fire someone on the spot like that, especially someone who is just one of the "multiple hands" responsible for creating and approving ads?
I wonder if Anon also complained to Deborah Dick-Rath over at MM&M. She wrote her critical piece about the Replax print ad way before I did. She really ripped into the creative team: "And while the Relpax creative team put in a valiant effort, in the end, they were defeated by too many typefaces, too much copy, too many messages and a somewhat unfortunate choice in art direction."
I suppose she gets a free pass because she started out with praise, faint though it was.
Maybe this doesn't have anything to do with Relpax at all. I just can't recall, however, any recent critical posts I have made that may have gotten Anon fired.
Anyway, I assume Anon will be able to collect a couple of years of unemployment insurance, unless Congress refuses to extend that benefit. When I was laid off many years ago during the dotcom bust, I only received 26 weeks of unemployment insurance - damn George Bush and those Republicans!
Subscribe to:
Posts (Atom)


